سعر اوجيداكلا 60 مجم 28 قرص 2026

Film-coated tablets containing daclatasvir 60 mg (AUG Pharma, Egypt), an HCV NS5A inhibitor used in combination regimens for chronic hepatitis C; 28 tablets per pack.

• Chronic hepatitis C virus infection in adults, in combination with other medicinal productsPopulation: AdultsEuropean Medicines Agency (EMA)

• In combination with sofosbuvir, the most frequently reported adverse reactions were fatigue, headache and nausea.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to daclatasvir or to any of the excipients.International label, same formulation · European Medicines Agency (EMA)
• Co-administration with strong CYP3A4 and P-gp inducers (loss of efficacy), including phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone and St John's wort.International label, same formulation · European Medicines Agency (EMA)

• Must not be administered as monotherapy; always use in combination with other medicinal products for chronic HCV, and the warnings of those products also apply.International label, same formulation · European Medicines Agency (EMA)
• Severe bradycardia and heart block have been observed when daclatasvir is used with sofosbuvir and concomitant amiodarone; the mechanism is not established.International label, same formulation · European Medicines Agency (EMA)
• Hepatitis B virus reactivation, some cases fatal, has been reported during or after treatment with direct-acting antivirals; screen all patients for HBV before starting and monitor HBV/HCV co-infected patients.International label, same formulation · European Medicines Agency (EMA)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, ritonavir-boosted regimens)Reduce the daclatasvir dose to 30 mg once daily.European Medicines Agency (EMA)
• Moderate CYP3A4 inducers (e.g., efavirenz)Increase the daclatasvir dose to 90 mg once daily.European Medicines Agency (EMA)
• Strong CYP3A4/P-gp inducersContraindicated because of lower daclatasvir exposure and loss of efficacy.European Medicines Agency (EMA)

• Embryotoxic and teratogenic in animal studies; not to be used during pregnancy or in women of childbearing potential not using contraception. Highly effective contraception should continue for 5 weeks after completion of therapy.International label, same formulation · European Medicines Agency (EMA)
• Unknown whether daclatasvir is excreted in human milk; animal data show excretion in milk and a risk to the infant cannot be excluded. Mothers should be instructed not to breast-feed while taking daclatasvir.International label, same formulation · European Medicines Agency (EMA)

• Daclatasvir (salt form not stated): Inhibits HCV non-structural protein 5A (NS5A), an essential component of the viral replication complex, blocking viral RNA replication and virion assembly.